Cytomedix actively targets perfusionists, orthopedic specialists, surgeons and wound care clinicians in various care settings for Angel® and AutoloGel™ PRP Systems. As members of the surgical team, perfusionists and other technologists, routinely manage various types of blood products including autologous PRP.

During surgical procedures, PRP can be applied directly or mixed with bone graft material prior to wound application. Growth factors released by platelets present in PRP have been shown to aid in the healing process. For many technicians, the Angel® Whole Blood Separation System is the preferred PRP System as it is the only closed PRP System designed for surgical use with variable blood processing volumes and consistent platelet concentration.

The AutoloGel™ PRP System is viewed as an essential wound management solution in chronic non-healing wounds by a growing number of satisfied customers. In settings such as long-term acute care hospitals, the U.S. Department of Veterans Affairs, and public health services groups such as the Indian Health Services, where the treatment costs for non healing wounds are growing rapidly, AutoloGel™ PRP has demonstrated amazing results, particularly in recalcitrant, non healing ulcers.

Findings from a prospective case series evaluating the short term impact of AutoloGel™ PRP, confirmed effectiveness in non-healing wounds with an average duration of 48 weeks. The AutoloGel™ PRP produced a favorable clinical response in 97% of the wounds treated, resulting in a mean reduction in wound volume of 62% in less than three weeks of treatment on average.

Non healing diabetic foot ulcers that can result in amputations, are major costs to the health care system. Cost-effective alternatives for non-healing wounds such as the AutoloGel™ System, can reduce the lifetime wound management costs that can be beneficial for the patient, the provider and the payor.